Discovering Last Month's Psoriasis Spotlight
The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.
A Puzzling Case of Redness in Atopic Dermatitis
A patient with atopic dermatitis presents with redness and other unusual symptoms. What's the diagnosis?
Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports
Investigators reported successful treatment of psoriasis with risankizumab, despite presence of concomitant HIV infection in 4 male patients.
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
Raj Chovatiya, MD, PhD, shares his atopic dermatitis insights.
Derm In The News: September 24-30
Keep up with the latest headlines in dermatology from the past week, including new research into artificial intelligence skin tone bias, dermatologic care of the unhoused patient population, and more.
Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence
Sachin Shridharani, MD, discusses the results of a recent Allergan Aesthetics study exploring the efficacy of onabotulinumtoxinA in treating platysma prominence.
Abeona Submits Biologics License Application to FDA for EB-101
Abeona Therapeutics is seeking Priority Review and approval of the therapy for patients with recessive dystrophic epidermolysis bullosa.
Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says
A single-arm, prospective trial found that botulinum toxin injections did not have a significant effect on symptoms one month after treatment.
POLL: What Strategies Have You Found Most Effective in Managing Alopecia?
Derm In The News: September 17-23
Keep up with the latest headlines in dermatology from the past week, including efforts to raise awareness about the importance of skin checks and sun protection, CeraVe's role in expanding a dermatology residency training program, and more.
Combination Treatments in HS Require Further Review
A systematic review found that generally, combination therapy has evidence supportive of its efficacy in hidradenitis suppurativa.
Native American and Indigenous Communities Face Dermatologic Barriers to Care, Disparities, and More
Today is National Native American Day. Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Native and Indigenous communities.
The Cutaneous Connection: The Dermatologists' Role in Health Care & Legislative Advocacy ft. Marty Makary, MD, MPH, FACS
Public health/public policy researcher and New York Times best-selling author Marty Makary, MD, MPH, FACS, discusses the role of physician-led legislative advocacy in health care and dermatology.
Previewing Dermatology Times Editorial Advisory Board Member Sessions: Science of Skincare Summit 2023
Among the many sessions to be held at the 2023 Science of Skincare Summit in Austin, Texas, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.
Considerations for Preventing and Addressing Alopecia in Patients With Religious Headwear
Prior research has demonstrated an association between religious headwear and traction alopecia.
Navigating Topical Steroid Withdrawal and Extreme Adverse Reactions to Corticosteroids
Peter Lio, MD, offers perspectives on topical steroid withdrawal, also known as red skin syndrome or topical steroid addiction.
Dupilumab Steadily Reduces IgE Levels of Patients With Atopic Dermatitis
Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.
Addressing Cultural Disconnect in Patients With Vitiligo
Clinicians can use culturally competent care to ease patients’ concerns with identity and better understand the emotional toll of the condition.
VISIBLE Study Paves Way for More Equitable Psoriasis Research
The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.
Psychiatric Comorbidities Present in 1 in 4 Patients With HS
Affective, anxiety, and neurotic disorders were among the most common in a recent study.
POLL: Do You Routinely Inquire About Your Patients' Skin Care Routines and Habits?
This Skin Care Awareness Month, we want to hear more about your experiences with discussing skin care habits with your patients. Click to answer this week's poll.
Derm In The News: September 10-16
Keep up with the latest headlines in dermatology from the past week, including advances in diversifying the specialty, artificial skin and its role in eczema research, and more.
Dermatologic Concerns and Disparities Among Members of the Hispanic Community
This Hispanic Heritage Month, Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Hispanic community.
Long Pulsed ND:YAG Laser Efficacious in Treatment of Plane Warts
In a study of 19 patients, the laser treatment led to excellent responses in 86.36% of participants, with 78.94% achieving complete response.
Atopic Dermatitis, Systemic Inflammation Not Linked to Dementia Risk
According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.
Use of High-Frequency Ultrasound Can Improve Diagnostic Accuracy and Determinacy of Subcutaneous Lesions
Indeterminacy of invisible subcutaneous lesions such as epidermoid cysts, lipomas, pilomatrixomas, hemangiomas, and DFSPs, can be decreased with HFUS use, according to investigators.
Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe AD Met Clinical Efficacy Endpoints
Nektar Therapeutics announced the promising and statistically significant results, which included meeting endpoints of BSA, DLQI and POEM in patients with atopic dermatitis.
Finasteride and Hydroxychloroquine Deemed Equally Effective in Treatment of Frontal Fibrosing Alopecia
Researchers compared the efficacy of the 2 modalities and found that they were equal in safety, efficacy, and tolerability.
Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older
The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.
Steven Dayan, MD, FACS: Prioritizing Patient Satisfaction in Cosmetic Dermatology
Steven Dayan, MD, FACS, first author behind a recent study involving high rates of patient satisfaction following treatment with botulinum toxin, discusses the importance of placing patient satisfaction at the forefront of cosmetic dermatology.
2 Clarke Drive Cranbury, NJ 08512